Control and inhibition analysis of complex formation processes

详细信息    查看全文

• 作者：Takashi Saitou (1)
  Keiko Itano (1)
  Daisuke Hoshino (2)
  Naohiko Koshikawa (2)
  Motoharu Seiki (2)
  Kazuhisa Ichikawa (3)
  Takashi Suzuki (1)
  
• 关键词：Control analysis ; Complex formation ; Biochemical reaction kinetics ; Proteinase inhibitors ; Cancer invasion ; Matrix metalloproteinases
• 刊名：Theoretical Biology and Medical Modelling
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：9
• 期：1
• 全文大小：682KB
• 参考文献：1. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. / Crit Rev Oral Biol Med 1993,4(2):197鈥?50.
  2. Nagase H, Woessner JF Jr: Matrix metalloproteinases. / J Biol Chem 1999,274(31):21491鈥?1494. CrossRef
  3. Overall CM, Kleifeld O: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. / Nat Rev Cancer 2006,6(3):227鈥?39. CrossRef
  4. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H: Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. / Eur J Biochem 1990,194(3):721鈥?30. CrossRef
  5. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. / Nature 1994,370(6484):61鈥?5. CrossRef
  6. Seiki M: Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. / Cancer Lett 2003,194(1):1鈥?1. CrossRef
  7. Itoh Y, Seiki M: MT1-MMP: a potent modifier of pericellular microenvironment. / J Cell Physiol 2006,206(1):1鈥?. CrossRef
  8. Higgins J: Analysis of sequential reactions. / Ann N Y Acad Sci 1963, 108:305鈥?21. CrossRef
  9. Kacser H, Burns JA: The control of flux. / Biochem Soc Trans 1995, 23:341鈥?66.
  10. Heinrich R, Rapoport T: A linear steady-state treatment of enzymatic chains. general properties, control and effector strength. / Eur J Biochem 1974, 42:89鈥?5. CrossRef
  11. Heinrich R, Rapoport T: A linear steady-state treatment of enzymatic chains. critique of the crossover theorem and a general procedure to indentify interactions sites with an effector. / Eur J Biochem 1974, 42:97鈥?05. CrossRef
  12. Fell DA: Metabolic control analysis: a survey of its theoretical and experimental development. / Biochem J 1992, 286:313鈥?30.
  13. Colquhoun D, Dowsland KA, Beato M, Plested AJR: How to impose microscopic reversibility in complex reaction mechanisms. / Biophys J 2004, 86:3510鈥?518. CrossRef
  14. Yang J, Bruno WJ, Hlavacek WS, Pearson J: On imposing detailed balance in complex reaction mechanisms. / Biophys J 2006, 91:1136鈥?141. CrossRef
  15. Ederer M, Gilles ED: Thermodynamically feasible kinetic models of reaction networks. / Biophys J 2007,92(6):1846鈥?857. CrossRef
  16. Hoshino D, Koshikawa N, Suzuki T, Quaranta V, Weaver A, Seiki M, Ichikawa K: Establishment and validation of computational model for MT1-MMP dependent ECM degradation and intervention strategies. / PLoS Comput Biol 2012,8(4):e1002479. CrossRef
  17. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS: Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. / Lab Invest 2004,84(1):8鈥?0. CrossRef
  18. Karagiannis ED, Popel AS: A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. / J Biol Chem 2004,279(37):39105鈥?9114. CrossRef
  19. Toth M, Bernardo MM, Gervasi DC, Soloway PD, Wang Z, Bigg HF, Overall CM, DeClerck YA, Tschesche H, Cher ML, Brown S, Mobashery S, Fridman R: Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. / J Biol Chem 2000, 275:41415鈥?1423. CrossRef
  20. Olson MW, Gervasi DC, Mobashery S, Fridman R: Kinetic analysis of the binding of human matrix metalloproteinase-2 and 鈭? to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. / J Biol Chem 1997,272(47):29975鈥?9983. CrossRef
  21. Howard EW, Banda MJ: Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. / J Biol Chem 1991,266(27):17972鈥?7977.
  22. Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, Docherty AJ: The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. / Biochem J 1992, 283:637鈥?41.
  23. Karagiannis ED, Popel AS: Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: Insights from a computational model. / J Theor Biol 2006, 238:124鈥?45. CrossRef
  24. Saitou T, Rouzimaimaiti M, Koshikawa N, Seiki M, Ichikawa K, Suzuki T: Mathematical modeling of invadopodia formation. / J Theor Biol 2012, 298:138鈥?46. CrossRef
  
• 作者单位：Takashi Saitou (1)
  Keiko Itano (1)
  Daisuke Hoshino (2)
  Naohiko Koshikawa (2)
  Motoharu Seiki (2)
  Kazuhisa Ichikawa (3)
  Takashi Suzuki (1)
  
  1. Division of Mathematical Science, Department of Systems Innovation, Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama, Toyonaka, Osaka, 560-8581, Japan
  2. Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
  3. Mathematical Oncology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
  
• ISSN：1742-4682

文摘

Background Proteolytic degradation of the extracellular matrix (ECM) is a key event in tumour metastasis and invasion. Matrix metalloproteinases (MMPs) are a family of endopeptidases that degrade most of the components of the ECM. Several broad-spectrum MMP inhibitors (MMPIs) have been developed, but have had little success due to side effects. Thus, it is important to develop mathematical methods to provide new drug treatment strategies. Matrix metalloproteinase 2 (MMP2) activation occurs via a mechanism involving complex formation that consists of membrane type 1 MMP (MT1-MMP), tissue inhibitor of matrix metalloproteinase 2 (TIMP2) and MMP2. Here, we focus on developing a method for analysing the complex formation process. Results We used control analysis to investigate inhibitor responses in complex formation processes. The essence of the analysis is to define the response coefficient which measures the inhibitory efficiency, a small fractional change of concentration of a targeting molecule in response to a small fractional change of concentration of an inhibitor. First, by using the response coefficient, we investigated models for general classes of complex formation processes: chain reaction systems composed of ordered steps, and chain reaction systems and site-binding reaction systems composed of unordered multi-branched steps. By analysing the ordered step models, we showed that parameter-independent inequalities between the response coefficients held. For the unordered multi-branched step models, we showed that independence of the response coefficients with respect to equilibrium constants held. As an application of our analysis, we discuss a mathematical model for the MMP2 activation process. By putting the experimentally derived parameter values into the model, we were able to conclude that the TIMP2 and MMP2 interaction is the most efficient interaction to consider in selecting inhibitors. Conclusions Our result identifies a new drug target in the process of the MMP2 activation. Thus, our analysis will provide new insight into the design of more efficient drug strategies for cancer treatment.